|Bid||61.9500 x 900|
|Ask||62.1300 x 800|
|Day's Range||60.48 - 62.35|
|52 Week Range||29.56 - 70.50|
|Beta (3Y Monthly)||0.82|
|PE Ratio (TTM)||120.82|
|Earnings Date||Feb 20, 2019 - Feb 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||66.00|
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return Read More...
The Dow Jones industrial average is leading another rebound on Wall Street following a sharp pullback in recent days. Chipotle, Attunity, Repligen and McDonald's are acting bullishly.
NEW YORK, Nov. 12, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Repligen stock is on a rampage this year as it outperforms broad medical-products stocks. The bioprocessing firm has completely transformed, its CEO says.
An underrated biotech, a boring industrials play, and an intriguing cloud company: Here's why these growth stocks deserve your attention.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 1) Gritstone Oncology Inc (NASDAQ: GRTS ) Repligen Corporation ...
Repligen is the IBD Stock Of The Day after the bioprocessor broke out for the second time this year on its 15th straight quarter of double-digit sales growth. Shares rose.
The Waltham, Massachusetts-based company said it had net income of 10 cents per share. Earnings, adjusted for non-recurring costs, were 20 cents per share. The results topped Wall Street expectations. ...
- Webcast and Conference Call to Be Held Thursday, November 1, 2018 at 8:30 a.m. EDT - WALTHAM, Mass., Oct. 22, 2018 -- Repligen Corporation (NASDAQ:RGEN) today announced that.
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Based on Repligen Corporation’s (NASDAQ:RGEN) earnings update in June 2018, analyst consensus outlook appear pessimistic, with profits predicted to drop by -13% next year against the past 5-year average growth Read More...
Repligen (RGEN) delivered earnings and revenue surprises of -11.11% and 3.62%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?